Results 121 to 130 of about 616,871 (170)

Menin Inhibitors Trigger Leukemia Remissions

Cancer Discovery, 2023
Abstract Menin inhibitors have proven effective in patients with acute leukemias. A phase II study of revumenib yielded a response rate of 63% in patients with relapsed or refractory disease and KMT2A rearrangements; a phase I trial combining the drug with three chemotherapies also yielded complete remissions in patients with acute ...
openaire   +2 more sources

Menin: from molecular insights to clinical impact

Epigenomics
Menin, the protein product of the MEN1 gene, is essential for development and has been implicated in multiple different cancer types. These include leukemias and several different solid tumors, including neuroendocrine tumors.
Yadira M Soto-Feliciano, Yadira Soto Feliciano, Margaret Brown   +2 more
exaly   +2 more sources

Menin-MLL Inhibitor MI-503 Blocks Menin Nuclear Export and Suppresses Hypergastrinemia

2022
Abstract Menin is the protein product of the Multiple Endocrine Neoplasia 1 ( MEN1 ) gene locus at 11q13 and is a known tumor suppressor of neuroendocrine neoplasms (NENs). Gastrin-expressing NENs (gastrinomas) comprise the most frequent and malignant of the MEN1-dependent endocrine
Juanita L. Merchant, Zhen Wang, Sinju Sundaresan   +2 more
openaire   +1 more source

Discerning the Landscape of Menin Inhibitor Resistance

Blood
Background: The Phase 1 AUGMENT-101 trial demonstrated that the menin inhibitor (MI) revumenib has promising activity in KMT2A-rearranged (KMT2A-r) and nucleophosmin mutant (NPM1m) acute leukemias, however 40% of patients with available DNA samples developed menin (MEN1) mutations and some ...
Wallace Bourgeois, Jevon Cutler, Hannah E Rice, Brandon Regalado, Daniela V. Wenge, Florian Perner, John G. Doench, Jerry M McGeehan, Scott A Armstrong   +8 more
openaire   +1 more source

Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)

Expert Opinion on Therapeutic Patents, 2022
Minhang Xin, San-Qi Zhang
exaly  

Inhibitors of menin-MLL interaction

2021
BUTLER THOMAS, PALMER JIM, UPASANI RAVI, WELSCH MATTHEW, VEMPATI SRIDHAR, KELLY BRENDAN, PAINTER EDWARD   +6 more
openaire   +3 more sources

Menin–KMT2A interaction inhibitor shows promise

Nature Reviews Clinical Oncology, 2023
openaire   +2 more sources

Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia

Journal of Medicinal Chemistry, 2021
Minhang Xin, Hong-Yi Zhao, Shuai Mao
exaly  

Investigating menin inhibitor action in leukaemia

Nature Reviews Drug Discovery, 2023
openaire   +1 more source

PIPERIDINE COMPOUNDS AS MENIN INHIBITORS

2021
WANG SHAOMENG, AGUILAR ANGELO, XU FUMING, ZHANG MENG, HUANG LIYUE, STUCKEY JEANNE, XU RENQI, ZHOU HAIBIN, XU SHILIN, LIU TAO   +9 more
openaire   +1 more source